z-logo
open-access-imgOpen Access
The prognostic value of CD49d expression in Turkish patients with chronic lymphocytic leukemia
Author(s) -
Ant Uzay,
Tayfur Toptaş,
Işık Kaygusuz,
Emel Demiralp,
Tülin Tuğlular,
Mahmut Bayık
Publication year - 2012
Publication title -
turkish journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 16
ISSN - 1300-7777
DOI - 10.5152/tjh.2012.03
Subject(s) - medicine , chronic lymphocytic leukemia , turkish , oncology , expression (computer science) , value (mathematics) , leukemia , statistics , linguistics , philosophy , mathematics , computer science , programming language
OBJECTIVE: The aim of this study was to assess the prognostic value of CD49d expression in Turkish chronic lymphocytic leukemia patients.\udMETHODS: Data for 118 patients from a single center were evaluated. In all, the study included 73 patients for whom complete clinical follow-up data, and flow cytometry test results for CD5/19, CD23/43, CD38, Zap- 70, Kappa, and Lambda light chains, and CD49d were available. The effect of the level of CD49d expression on overall survival (OS) and time to treatment (TTT) was investigated retrospectively.\udRESULTS: Patients with high CD49d expression (≥30%) had more advanced disease at the time of diagnosis (median Rai stage 3 vs. Rai stage 1, P = 0.03). Patients resistant to treatment had higher CD49d expression than patients that responded to treatment (mean CD49d expression of 58% vs. 46%, P = 0.08). The level of CD49d expression was not associated with OS or TTT.\udCONCLUSION: The study’s findings show that the patients with high CD49d expression at the time of diagnosis had more advanced disease and poorer response to therapy; however, their overall survival did not differ from that of the patients with advanced disease stage, but lower levels of CD49d expression

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here